- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04105920
Evaluation of the Interest of Hyaluronic Acid in the Preservation of Sexual Function During Prostate Curietherapies (HYALEREC)
Phase III Trial Randomized to Evaluate the Interest of Hyaluronic Acid in the Preservation of Sexual Function During Prostate Curietherapies
Prostate cancer is the most common cancer in humans, but low mortality, around 10 / 100,000 patients / year. It differs from other cancers by its high rate of cure, as well as a long term survival. Numerous treatment techniques are available and of comparable effectiveness: as a result it must be given importance to the short and long term side effects of these different treatments.
Prostate brachytherapy with permanent implants is thus one of the standard techniques for the treatment of localized prostate cancers of favorable grades (WHO grade 1-2).
In comparison with prostatectomy and RTE, brachytherapy allows low rates of long-term urinary toxicities, and comparable rates of erectile function preservation.
With regard to erectile dysfunction, their pathophysiology after irradiation is complex and poorly understood, including damage to the erector apparatus, innervation, vascularization, and of course the level of libido.
As an example, the radiotherapy team of the Lyon Sud hospital showed that the delivering a the lowest dose of radiation to the pudendal arteries and to the penile bulb during RTE, leads to erectile preservation rates comparable with those from the literature with nearly 85% of patients with erectile function retained at 2 years . They were also able to retrospectively show that a lower dose to the pudendal arteries correlated with better erectile function during brachytherapy.
The brachytherapy procedure requires general anesthesia and endorectal ultrasound, which are optimal conditions for injecting hyaluronic acid between the prostate, rectum, and pudendal arteries. This gesture has shown to induce very few morbidity. They want to demonstrate that the injection of hyaluronic acid during prostate brachytherapy will reduce the radiation dose to the pudendal arteries and penile bulb, and thus improve the rate of preservation of erectile function in selected patients.
This randomized phase III study comparing dyserection rates after CT performed with (Arm A) and without (Arm B) injection of HA, in a patient population without erectile dysfunction before treatment.
Study Overview
Detailed Description
Prostate cancer is the most common cancer in humans with an incidence of about 100 / 100,000 cases / year in Europe, but low mortality, around 10 / 100,000 patients / year. It differs from other cancers by its high rate of cure, as well as a long term survival. Numerous treatment techniques are available and of comparable effectiveness: as a result it must be given importance to the short and long term side effects of these different treatments.
Prostate brachytherapy with permanent implants is thus one of the standard techniques for the treatment of localized prostate cancers of favorable grades (WHO grade 1-2). The overall survival and survival rates without biochemical recurrence at 5 and 10 years are comparable to those of other techniques such as prostatectomy or external radiotherapy (RTE), exceeding 95%.
In comparison with prostatectomy and RTE, brachytherapy allows low rates of long-term urinary toxicities, and comparable rates of erectile function preservation.
With regard to erectile dysfunction, their pathophysiology after irradiation is complex and poorly understood, including damage to the erector apparatus, innervation, vascularization, and of course the level of libido.
As an example, the radiotherapy team of the Lyon Sud hospital showed that the delivering a the lowest dose of radiation to the pudendal arteries and to the penile bulb during RTE, leads to erectile preservation rates comparable with those from the literature with nearly 85% of patients with erectile function retained at 2 years (18.5% moderate erectile dysfunction at 2 years, for moderate to severe degradation rates usually seen between 30 and 70% after external beam radiotherapy. They were also able to retrospectively show that a lower dose to the pudendal arteries correlated with better erectile function during brachytherapy.
The brachytherapy procedure requires general anesthesia and endorectal ultrasound, which are optimal conditions for injecting hyaluronic acid between the prostate, rectum, and pudendal arteries. This gesture has shown to induce very few morbidity. They want to demonstrate that the injection of hyaluronic acid during prostate brachytherapy will reduce the radiation dose to the pudendal arteries and penile bulb, and thus improve the rate of preservation of erectile function in selected patients.
This randomized phase III study comparing dyserection rates after CT performed with (Arm A) and without (Arm B) injection of HA, in a patient population without erectile dysfunction before treatment.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Samy HORN, Dr
- Phone Number: +33 04 78 86 42 63
- Email: samy.horn@chu-lyon.fr
Study Contact Backup
- Name: Julien BERTHILLER, Dr
- Phone Number: +33 04 72 11 80 67
- Email: julien.berthiller@chu-lyon.fr
Study Locations
-
-
-
Dijon, France, 21079
- Recruiting
- Centre Jean François Leclerc
-
Principal Investigator:
- Magali QUIVRIN
-
Contact:
- Magali QUIVRIN
-
Grenoble, France, 38043
- Recruiting
- Radiothérapie, Hôpital A. Michallon, CHU de Grenoble
-
Contact:
- Carole IRIART, MD
-
Principal Investigator:
- Carole IRIART, MD
-
Pierre-Bénite cedex, France, 69495
- Recruiting
- Centre Hospitalier Lyon Sud
-
Contact:
- Samy HORN
- Phone Number: 04.78.86.42.55
- Email: samy.horn@chu-lyon.fr
-
Principal Investigator:
- Samy HORN
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged 18 to 80 years old.
- Patients over 75 years old must have a G8 score ≥ 14 or oncogeriatric assessment.The geriatrician's expertise will validate the brachytherapy treatment.
- Karnofsky performance status ≥ 60% (ECOG performance status 0-2)
- Patients diagnosed with histologically proven localized prostate adenocarcinoma
Prostate cancer eligible for brachytherapy according to the following criteria:
- at. Low risk prostate cancer: Gleason score <7 and PSA <10 ng / ml AND cT1-cT2a
- Intermediate risk prostate cancers with a single adverse factor: Gleason score = 7 (3 + 4) OR PSA 10-15ng / ml OR cT2b-cT2c / ml
- less than 50% positive biopsies
- Volume of the prostate <60 cc
- No middle lobe
- IPSS <15/35
- Initial IIEF5 score, no treatment, greater than or equal to 20/25
- Patient able to sign an informed consent form
- Patient benefiting from a social insurance system or similar system
Exclusion Criteria:
- Nodal or distant metastatic evolution
- History of abdominal or pelvic irradiation
- Anterior treatment for prostate cancer, including hormone therapy with LHRH analogue or GnRH antagonist.
- History of prostate resection, not allowing brachytherapy seeds implantation.
- Uncontrolled cancer (except basal cell skin cancer)
- Current clinical study that may interfere with this study
- Patient unable to complete a self-administered questionnaire and understand the ins and outs of the trial
- Major patients protected by law
- Allergy to hyaluronic acid
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: hyaluronic acid arm
Patients included in this arm, will have, before insertion of brachytherapy seeds in the prostate, an injection of hyaluronic acid between the prostate, rectum, and pudendal arteries
|
Patients included in this arm, will have, before insertion of brachytherapy seeds in the prostate, an injection of hyaluronic acid between the prostate, rectum, and pudendal arteries
|
Active Comparator: Conventional brachytherapy
Patients included in this arm will have the conventional brachytherapy.
|
Patients included in this arm, will have, before insertion of brachytherapy seeds in the prostate, an injection of hyaluronic acid between the prostate, rectum, and pudendal arteries
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
interest of Hyalurocnic injection to protect pudendal arteries during prostate brachytherapy in the preservation of Erectile function at 2years.
Time Frame: 2 years
|
The primary endpoints is the comparison between the 2 groups of the proportion of patient with preserved erectile function.
The erectile function will be assessed with the variation of IIEF-5 score between pre-treatment evaluation and 2years after treatment evaluation.
Erectile function will be considered preserved in the absence of a decrease in the IIEF-5 score by more than 5 points.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evolution of erectile function.
Time Frame: 2 years
|
comparison between the 2 groups of the International Index of Erectile Function (IIEF5) score evolution during the 2 years of follow-up.
|
2 years
|
The IPDE5 consumption at 2 years
Time Frame: 2 years
|
The consumption of IPDE5 at 2 years will be defined by the proportion of patients who have used IPDE5 at least once after the intervention.
|
2 years
|
Erection satisfaction at 2 years
Time Frame: 2 years
|
Erection satisfaction at 2 years will be measured using a numerical scale rated from 0 to 10, 0 being "not at all satisfied" and 10 "completely satisfied
|
2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Psychosocial dimensions
Time Frame: 2 years
|
the psychosocial dimensions of patients with erectile disfunction will be assessed using the initial EPIC (Expanded Prostate cancer Index composite / Sexual Component Questionnaire
|
2 years
|
Response assessment of IPDE5 (Phosphodiesterase 5 inhibitors ) treatement.
Time Frame: 6 months
|
Effects Assessment of phosphodiesterase type 5 inhibitors by the EDITS (Erectile Dysfunction Inventory of Treatment Satisfaction) questionnaire 6 months after treatment.
|
6 months
|
The incidence of acute gastrointestinal and gastrourinary toxicity
Time Frame: 6 months
|
Acute gastrointestinal and gastrointestinal toxicities are evaluated according to the V5 scale of CTCAE, initially at 6 weeks.
We will evaluate the grade 2 toxicities, and the number of grade 3 or 4 toxicities in each arm.
|
6 months
|
The incidence of late gastrointestinal and gastrourinary toxicity,
Time Frame: 2 years
|
Acute and late gastrointestinal and gastrointestinal toxicities are evaluated according to the V5 scale of CTCAE, at two years (late toxicities).
We will evaluate the grade 2 toxicities, and the number of grade 3 or 4 toxicities in each arm.
|
2 years
|
Evaluation of brachytherapy by CT-MRI fusion Imaging measuring
Time Frame: 45 days after brachytherapy
|
Quality criteria for brachytherapy will be defined on CT-MRI fusion imaging at 45 days after treatment.
|
45 days after brachytherapy
|
Thickness hyaluronique acide injection assessment
Time Frame: 24 hours after surgery
|
The quality of the injection of AH is defined by a thickness of AH ≥ 10 mm measured at the level of the prostatic apex.
|
24 hours after surgery
|
Link between hyaluronic acid and pudendal artery stenosis.
Time Frame: 2 years after treatment
|
The impact of hyaluronic acid injection on the probability of occurrence of pudendal artery stenosis will be assessed by centralized 2-year MRI revisions compared to MRI at day 45
|
2 years after treatment
|
Link between pudendal artheris stenosis occurrence and radiation dose received
Time Frame: 2 years after surgery
|
The occurrence of pudendal artery stenosis (defined by centralized 2-year MRI rereading) will be correlated with the maximum dose received by these structures (Dnear max = D2% urethra, ie the minimum dose received by 2% of patients).
the pudendal artery.
|
2 years after surgery
|
Link between pudendal arteries stenosis and erectile disfunction.
Time Frame: 2 years after treatment
|
probability of occurrence of erectile dysfunction years will be correlated with the possible observation of pudendal artery stenosis at 2 years.
|
2 years after treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Immunologic Factors
- Protective Agents
- Adjuvants, Immunologic
- Viscosupplements
- Hyaluronic Acid
Other Study ID Numbers
- 69HCL19_0298
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedRecurrent Prostate Carcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Hormone-Resistant Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Hyaluronic acid arm
-
Ayhman Al AfifNova Scotia Health AuthorityCompletedHead and Neck Neoplasms | Laryngeal Cancer | Head and Neck Squamous Cell Carcinoma | Voice Disorders
-
Herbarium Laboratorio Botanico LtdaCompletedVaginal Disease | Atrophic VaginitisBrazil
-
Chong Kun Dang PharmaceuticalUnknown
-
Bioventus LLCTerminatedKnee OsteoarthritisFrance, Monaco
-
Taipei Medical UniversityShin Kong Wu Ho-Su Memorial HospitalUnknown
-
Medical University of ViennaRecruiting
-
Tedec-Meiji Farma, S.A.CompletedOsteoarthritis of the KneeSpain
-
Federico II UniversityRecruiting
-
Hawler Medical UniversityCompleted
-
Istanbul UniversityCompletedKnee OsteoarthritisTurkey